

# Synthesis of 6-Hydroxy Derivatives of Steroidal Hormones by SeO<sub>2</sub> Mediated Oxidation

Rainer Strommer<sup>1</sup>, Claudia Hödl<sup>1</sup>, Wolfgang Strauss<sup>2</sup>,  
Reinhard Sailer<sup>2</sup>, Ernst Haslinger<sup>1</sup>, Hans Wolfgang Schramm<sup>1</sup>,  
and Christoph Seger<sup>1,\*;†</sup>

<sup>1</sup> Institute of Pharmaceutical Chemistry and Pharmaceutical Technology,  
University of Graz, A-8010 Graz, Austria

<sup>2</sup> Institute for Laser Technology in Medicine and Metrology, University of Ulm,  
D-89081 Ulm, Germany

Received March 2, 2004; accepted March 8, 2004

Published online June 30, 2004 © Springer-Verlag 2004

**Summary.** Selenium dioxide oxidation of molecules with cyclopentanoperhydrophenanthrene skeleton and allylic moieties, such as the well known human steroidal hormones progesterone and testosterone enables the syntheses of potential active 6 $\beta$ -hydroxysteroids.

**Keywords.** Selenium dioxide; NMR; Progesterone; Testosterone.

## Introduction

A wide variety of steroidal hormone derivatives have been synthesized over the past decades, many of them by introducing oxygen bearing functionalities in a highly stereoselective and regioselective manner. Because of their biological importance [1, 2], there has been an immense amount of work on the selective oxidation of steroid hormones. Nevertheless, only little attention has been paid to the introduction of functionalities into position 6 of the steroidal backbone. *Terasawa et al.* [3] oxidised a variety of halogenated corticosteroids with SeO<sub>2</sub> under different reaction conditions and prepared regioselectively the corresponding 6-hydroxydiastereomers. In this case, the stereospecificity of the reaction was driven by the steric influence of halogen substituents in position 9 directing the new hydroxy group in opposite direction to the halogen atom. We have shown [4], that

---

\* Corresponding author. E-mail: christoph.seger@uibk.ac.at

† Current address: Institute of Pharmacy, Department of Pharmacognosy, University of Innsbruck, A-6020 Innsbruck, Austria

in the case of mifepristone [5] a member of the steroidal 4-ene-3-one derivative family, the well known and thoroughly documented selenium dioxide [6–8] promoted allylic oxidation of double bonds [9–11] leads to  $6\alpha$ -hydroxy and  $6\beta$ -hydroxy mifepristone. Based on these findings we decided to investigate the general scope of this reaction for similar compounds and present here the reaction schemes for two prominent biogenic members – progesterone and testosterone.

## Results and Discussions


The allylic hydroxylation reaction was carried out by refluxing a suspension of the steroid under investigation with  $\text{SeO}_2$  yielding a mixture of desired derivatives and by-products in moderate yields. In accordance with the proposed reaction mechanism [12, 13],  $6\beta$ -hydroxy compounds are formed predominantly in the cases of progesterone and testosterone.

### Progesterone


The reaction of progesterone (**1**) with  $\text{SeO}_2$  proved that a selective introduction of a hydroxy group on position 6 of the steroid skeleton is possible. The main product,  $6\beta$ -hydroxyprogesterone (**2**) (Scheme 1), was isolated from the reaction mixture and purified by preparative HPLC and its structure was determined by NMR spectroscopy. The resonance of the olefinic proton H-4 shifted to lower field compared to the resonance of the proton in the starting material progesterone (from 5.72 to 5.80 ppm), and the  $\text{CH}_2$  signal of C-6 was replaced by a downfield shifted CH signal (72.9 ppm). The configuration of the new stereogenic centre in position 6 was determined from the coupling constant between H-6 and the H-7 protons. The signal of H-6 (4.38 ppm) showed no significant line splitting due to scalar coupling, thus excluding an axial coupling partner. Therefore this proton is located in the pseudoequatorial  $\alpha$  position at C-6.

### Testosterone

Oxidation of testosterone (**3**) with  $\text{SeO}_2$  yielded two major products in the ratio of 2:1 (Scheme 2). The main product was 6-hydroxytestosterone (**4**) and the NMR spectrum showed features similar to **2**, thus allowing to assign the stereochemistry of the introduced hydroxy function as  $\beta$ , too. The structure of the other isolated compound **5** was determined to be 2,17 $\beta$ -dihydroxy-1,4-androstadiene-3-on. An olefinic singulett at



Scheme 1



Scheme 2

7.05 ppm together with two carbon resonances at 126.8 (s, C-2) and 151.8 ppm (d, C-1) allowed to determine the position of the introduced double bond unequivocally to positions 1 and 2. An independent proof was possible by observing an NOE correlation signal between H-1 (7.15 ppm) and both H-11 (1.60 ppm) and CH<sub>3</sub>-19 (1.18 ppm).

In conclusion, these results demonstrate that SeO<sub>2</sub> oxidation enables selective hydroxylation in position 6 of certain steroidal 4-en-3-ones.

## Experimental

Mp: Büchi/Tottoli melting point apparatus; analytical TLC: precoated Al-backed 0.2 mm silicagel 60 F<sub>254</sub> plates (E. Merck), mobile phase: cyclohexane:AcOEt = 1:1; UV/Vis: Shimadzu UV-160 A (MeOH); IR: Perkin Elmer 1720-X (KBr); MS: Varian MAT-711 (70 eV); NMR: Varian Unity Inova 400 NMR spectrometer equipped with either tuneable broad band inverse probe tuned to <sup>13</sup>C for the inverse detected gradient selected 2D experiments or dual <sup>1</sup>H/<sup>13</sup>C probe for the 1D experiments. The measurements were carried out in CDCl<sub>3</sub>. The sample temperatures were kept at 300 K. Standard commercial pulse sequence programs were used. HMBC experiments were optimized for a long range coupling constant of 8 Hz. Shift values were referred to TMS.

### Selenium Dioxide Oxidation of Allylic Steroidal 4-En-3-ones

Allylic steroidal 4-en-3-ones (0.25 mmol) were dissolved in 50 cm<sup>3</sup> of dry dioxane in a 100 cm<sup>3</sup> three-neck flask with a reflux condenser. After addition of SeO<sub>2</sub> (33 mg) the mixture was stirred at 80°C under Ar until the slightly yellowish reaction mixture became red. The reaction was stopped after 20 h by addition of 30 cm<sup>3</sup> of 5% aqueous KOH. Thereafter, the solution was extracted four times with AcOEt, and the combined organic layers were washed with H<sub>2</sub>O to neutral pH, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated. A yellowish oil was obtained, which was further purified by column chromatography on silica (mobile phase: cyclohexane:AcOEt = 1:1). Separation of the single fractions was performed by preparative HPLC (Labomatic-HD-200/high pressure metering pump) on a Bischoff prep 3250, Prontoprep-120-10 C 18 HS 10 μm HPLC column (*l* = 500 mm, *d* = 32 mm); mobile phase: H<sub>2</sub>O:acetonitril = 65:35, flow: 25 cm<sup>3</sup>/min, detection: preparative UV-detector, 277 nm (Labocord 700 UV-VIS-spectrophotometer), pressure: 75 bar, injection volume: 5 cm<sup>3</sup>, amount of substance: up to 50 mg. Fractions containing desired products were lyophilized.

*6β-Hydroxy-4-pregnen-3,20-dion (2, C<sub>21</sub>H<sub>30</sub>O<sub>3</sub>)*

Yield 23%; mp 172°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 0.68 (s, 18-CH<sub>3</sub>), 0.95 (m, 9-H), 1.15 (m, 14-H), 1.24 (m, 7α-H), 1.30 (m, 15β-H), 1.37 (s, 19-CH<sub>3</sub>), 1.41 (m, 12α-H), 1.50 (m, 11α-H), 1.60 (m, 11β-H), 1.66 (m, 16β-H), 1.70 (m, 15α-H), 1.70 (m, 1α-H), 2.00 (m, 8-H), 2.01 (m, 7β-H), 2.08 (m, 1β-H), 2.10 (m, 12β-H), 2.15 (s, 21-CH<sub>3</sub>), 2.20 (m, 16β-H), 2.39 (m, 2α-H), 2.50 (m, 2β-H), 2.55 (m, 17α-H), 4.38 (m, 6α-H), 5.80 (s, 4-H) ppm; <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 13.2 (C-18), 19.4 (C-19), 20.8 (C-11), 22.7 (C-16), 24.2 (C-15), 29.6 (C-8), 31.3 (C-21), 34.0 (C-2), 37.0 (C-1), 37.8 (C-10), 38.3 (C-7), 38.5 (C-162), 43.8 (C-13), 53.4 (C-18), 55.9 (C-14), 63.4 (C-17), 72.9 (C-6), 126.3 (C-4), 167.7 (C-5), 199.9 (C-3), 209.0 (C-20) ppm; IR (KBr):  $\bar{\nu}$  = 3421 (m,  $\nu_{\text{OH}}$ ), 2926 (w,  $\nu_{\text{CC}}$ ), 2866 (w,  $\nu_{\text{CH}}$ ), 1699, 1681 (s,  $\nu_{\text{CO}}$ ) cm<sup>-1</sup>; UV/Vis (MeOH):  $\lambda_{\text{max}}$  = 230 nm; R<sub>f</sub> = 0.25; MS (70 eV): *m/z* (%) = 330.5 (M<sup>+</sup>, 100), 315 (28), 227 (20), 152 (55), 91 (35).

*6β,17β-Dihydroxy-4-androsten-3-on (4, C<sub>19</sub>H<sub>28</sub>O<sub>3</sub>)*

Yield 24%; mp 205°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 0.80 (s, 18-CH<sub>3</sub>), 0.92 (m, 9-H), 0.98 (m, 14-H), 1.10 (m, 12α-H), 1.22 (m, 7α-H), 1.37 (m, 15β-H), 1.39 (s, 19-CH<sub>3</sub>), 1.39 (m, 16-H), 1.45 (m, 11β-H), 1.55 (m, 11α-H), 1.62 (m, 15α-H), 1.72 (m, 1β-H), 1.89 (m, 12β-H), 1.99 (m, 8-H), 2.00 (m, 7β-H), 2.03 (m, 1α-H), 2.04 (m, 16-H), 2.39 (m, 2α-H), 2.56 (m, 2β-H), 3.65 (t, *J* = 6.7 Hz, 17α-H), 4.36 (m, 6α-H), 5.81 (s, 4-H) ppm; <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 11.1 (C-18), 19.6 (C-19), 20.6 (C-11), 23.3 (C-15), 29.8 (C-8), 30.5 (C-16), 34.2 (C-2), 36.4 (C-12), 37.1 (C-1), 38.1 (C-7), 38.2 (C-10), 42.9 (C-13), 50.5 (C-14), 53.8 (C-9), 73.1 (C-6), 81.7 (C-17), 126.3 (C-4), 168.0 (C-5), 200.1 (C-3) ppm; IR (KBr):  $\bar{\nu}$  = 3411 (m, OH-valence), 2938 (m,  $\nu_{\text{CC}}$ ), 1663 (s,  $\nu_{\text{CO}}$ ) cm<sup>-1</sup>; UV/Vis (MeOH):  $\lambda_{\text{max}}$  = 236 nm; R<sub>f</sub> = 0.19; MS (70 eV): *m/z* (%) = 304.2 (M<sup>+</sup>, 100), 289 (32), 152 (10), 91 (24), 57 (68).

*2,17β-Dihydroxy-1,4-androstadien-3-on (5, C<sub>19</sub>H<sub>26</sub>O<sub>3</sub>)*

Yield 11%; mp 174°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ = 0.78 (s, 18-CH<sub>3</sub>), 0.88 (m, 9-H), 0.90 (m, 14-H), 0.95 (m, 12-H), 0.98 (m, 7-H), 1.18 (s, 19-CH<sub>3</sub>), 1.35 (m, 15-H), 1.44 (m, 16-H), 1.52 (m, 11-H), 1.56 (m, 12-H), 1.60 (m, 11-H), 1.62 (m, 8-H), 1.80 (m, 15-H), 1.96 (m, 7-H), 2.05 (m, 16-H), 2.42 (m, 6-H), 3.54 (m, 17-H), 6.09 (s, 4-H), 7.15 (s, 1-H) ppm; <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ = 10.8 (C-18), 18.6 (C-19), 22.4 (C-11), 23.3 (C-15), 30.3 (C-16), 32.2 (C-6), 33.0 (C-7), 35.3 (C-8), 36.2 (C-12), 43.0 (C-13), 46.2 (C-10), 50.2 (C-14), 53.0 (C-9), 81.4 (C-17), 121.8 (C-4), 126.8 (C-2), 151.8 (C-1), 170.6 (C-5), 183.6 (C-3) ppm; IR (KBr):  $\bar{\nu}$  = 3447 (b,  $\nu_{\text{OH}}$ ), 2935 (m,  $\nu_{\text{CC}}$ ), 1644 (m,  $\nu_{\text{CO}}$ ) cm<sup>-1</sup>; UV/Vis (MeOH):  $\lambda_{\text{max}}$  = 215, 257 nm; R<sub>f</sub> = 0.17; MS (70 eV): *m/z* (%) = 302.2 (M<sup>+</sup>, 100), 286 (16), 122 (95), 91 (35), 57 (24).

## Acknowledgements

This work was supported by the Interdisciplinary Center of Medical Research (IZKF, project C-3) of the University of Ulm (grant number 01 KS 9605/2, Federal Ministry of Education and Research). The authors gratefully thank Dr. O. Kunert for measuring the NMR spectra.

## References

- [1] Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu E (1982) *Cr Acad Ser (Paris)* **294**: 933
- [2] Bertagna X, Bertagna C, Luton JP, Husson MJ, Girard F (1984) *J Clin Endocr Metab* **59**: 25
- [3] Terasawa T, Okada T (1991) *Synth Commun* **21**: 307
- [4] Strommer R, Strauß W, Sailer R, Emmert H, Steiner R, Reisinger E, Haslinger E, Schramm HW (2001) *Monatsh Chem* **132**: 387

- [5] Teutsch G, Ojasoo T, Raynaud JP (1988) *J Steroid Biochem* **31**: 549
- [6] Rabjohn N (1976) In: Dauben WG (ed) *Organic Reactions*, vol 24. Wiley, New York, p 261
- [7] Dunn AD (1999) *Org Prep Proc Int* **31**: 120
- [8] Hong-Seok K, Jung-Ho K (2001) *Bull Korean Chem Soc* **22**: 1390
- [9] Meystre C, Frey H, Voser W, Wettstein A (1956) *Helv Chim Acta* **39**: 734
- [10] Rosenheim O, Starling WW (1937) *J Chem Soc* 377
- [11] Shibuya K (1994) *Synth Commun* **24**: 2923
- [12] March J (1992) *Reactions, Mechanisms and Structure*. Wiley, New York, 698
- [13] Fieser LF, Fieser M (1967) *Reagents for Organic Synthesis*, vol 1. Wiley, New York, p 992